Quick Answer
BioXcel Therapeutics, Inc. reported Operating Income of -$50.46 million for fiscal year 2025.
BioXcel Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$50.46M | +25.0% |
| 2024 | -$67.25M | +60.9% |
| 2023 | -$171.78M | -7.6% |
| 2022 | -$159.65M | -49.3% |
| 2021 | -$106.94M | -29.9% |
| 2020 | -$82.30M | -144.9% |
| 2019 | -$33.60M | -68.3% |
| 2018 | -$19.96M | -340.0% |
| 2017 | -$4.54M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.23M | +7.0% | +10.2% |
| June 30, 2025 | -$15.85M | +8.3% | -57.0% |
| March 31, 2025 | -$10.10M | +58.2% | +34.0% |
| September 30, 2024 | -$15.29M | +68.3% | +11.6% |
| June 30, 2024 | -$17.30M | +67.0% | +28.4% |
| March 31, 2024 | -$24.16M | +52.8% | +50.0% |
| September 30, 2023 | -$48.30M | -23.9% | +7.9% |
| June 30, 2023 | -$52.41M | -44.4% | -2.4% |
- BioXcel Therapeutics, Inc. showed an increase of +25.0% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, BioXcel Therapeutics, Inc.’s operating income has declined by 1012.2% (from -$4.54 million to -$50.46 million).
- The most recent figure is from BioXcel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: